PEOPLE

Andrew Fesnak, MD

Assistant Professor of Clinical Pathology and Laboratory Medicine
University of Pennsylvania Perelman School of Medicine

Contact Information3400 Spruce Street
3 Ravdin Building - R3067
Philadephia, PA, 19104
Office: 215-662-3325

Email: fesnak@pennmedicine.upenn.edu

Specialty Division

Transfusion Medicine & Therapeutic Pathology

Education

BA (Molecular Biology), Princeton University, 2005
MD (Medical Doctorate), University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011
MHI (Masters of Health Care Innovation), University of Pennsylvania, 2019

Specialty Certification

Clinical Pathology, American Board of Pathology, 2014
Blood Banking / Transfusion Medicine, American Board of Pathology, 2015
Laboratory Management, Laboratory Management University, American Society for Clinical Pathology, 2015

Postgraduate Training

Resident, Clinical pathology, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2011-2014
Research fellow, Immunology, Perelman School of Medicine, University of Pennsylvania, 2012-2015
Clinical fellow, Transfusion medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2014-2015
Clinical fellow, Cell therapy, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2015-2016

Awards and Honors

Inductee, Gold Humanism Honor Society, 2011
The Kevin E. Salhany, MD Award for Excellence in Clinical Teaching, Department of Pathology and Laboratory Medicine Penn Medicine, 2016

Memberships and Professional Organizations

College of American Pathologists (CAP), 2011 - 2013
American Society for Clinical Pathology (ASCP), 2011 - Present
AABB, 2011 - Present
International Society for Cellular Therapy (ISCT), 2011 - Present
TerumoBCT, 2017 - 2017
Foundation for the Accreditation of Cellular Therapy (FACT), 2018 - Present
American Society for Apheresis (ASFA), 2018 - Present
National Heart, Blood and Lung Institute (NHLBI), 2019 - 2019

Web Links


Selected Publications

Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells)

Xu J, Gohil M, Stadtmauer E, Fraietta JA, Gonzalez VE, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine BL, Lacey S, June C, Davis MM, Cytotherapy 22(5): S35-S36, 2020

Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products

Gladney W, Hexner E, Salas-McKee J, Fesnak A, Jadlowsky J, Plesa G, Leskowitz R, Chew A, Dai A, Gohil M, Xu J, Siegel D, Lacey S, Davis MM, June C, Cytotherapy 22(5): S35, 2020

CRISPR-engineered T cells in patients with refractory cancer

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH, Science, 2020, PMID:32029687

Read article

Place of Academic GMP Facilities in Modern Cell Therapy

Bersenev A, Fesnak A, Cell Reprogramming for Immunotherapy: Methods and Protocols, 2020

The Challenge of Variability in Chimeric Antigen Receptor T Cell Manufacturing

Fesnak, A, Regenerative Engineering and Translational Medicine, 2019

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies

Wang K, Liu YI, Li J, Wang B, Bishop R, White C, DAS A, Levine AD, Ho L, Levine BL, Fesnak AD, Cytotherapy, 2019, PMID:31445816

Read article

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Garfall, AL et al., Blood 134(Supplement 1): 1863-1863, 2019

A Training and Employment Survey

Fesnak, A, Telegraft, International Society Cell & Gene Therapy Member Newsletter 26(3): , 2019

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Stadtmauer, EA et al., Blood 134(Supplement 1): 49-49, 2019

Good Manufacturing Practices Facilities for Cellular Therapy

Fesnak A, Levine B, Immunotherapy in Translational Cancer Research, 2018

Search PubMed for articles